);

   

About Oyster Point

Oyster Point is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company’s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the Trigeminal Parasympathetic Pathway (TPP) to activate the glands responsible for tear film production. The parasympathetic nervous system (PNS) is part of the involuntary nervous system responsible for regulating homeostasis, the “rest and digest” system, and is an important pathway for basal tear film production. Oyster Point Pharma is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate tear film production in patients with Dry Eye Disease (DED).

It is estimated that about 34M people in the U.S.1 and more than 300 million people globally2 suffer from Dry Eye Disease (DED), a multifactorial condition of the ocular surface characterized by a loss of homeostasis of the tear film.3 Despite the massive prevalence, prescription treatment options are limited. Oyster Point’s therapy is delivered in a nasal spray and is intended to directly target and stimulate the trigeminal parasympathetic pathway, which innervates the Lacrimal Functional Unit (LFU), and promote natural tear film production. This novel approach has the potential to improve both the signs and symptoms of DED with the goal of benefiting millions of people suffering from the burden of DED.

Oyster Point Pharma, named after the Oyster Point waterfront on San Francisco Bay, was founded in 2015 and is headquartered in Princeton, New Jersey.

Leadership

Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories.

JEFFREY NAU, PhD, MMS

President and Chief Executive Officer

Jeff has built his career on developing novel, innovative therapies for diseases of the eye, with over 15 years of experience working with biotechnology, pharmaceutical, and medical device companies. Most recently, he was VP, Clinical and Medical Affairs, at Ophthotech. Prior to that he was a Medical Science Director at Genentech working on the development of Lucentis®, a transformative drug for retinal diseases. Jeff has raised more than $150 million in equity for start-ups such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc. He has numerous patents and peer-reviewed publications. Jeff holds a Master’s in Medical Science and a PhD in Public Health and Epidemiology.

MARK MURRAY

Chief Financial Officer

Mark has been a CFO in the life science sector for over 30 years, working with senior executives and their boards. His eye care experience includes the successful exits of OptiMedica and Oculeve. Mark spent over 20 years with Guidant Corporation, where he was part of the senior management team and in its $1 billion IPO thru its exit in 2006 for $27 billion (by Boston Scientific and Abbott Labs). He has helped raise over $1.6 billion in equity and over $500 million in debt for public and private companies. Mark is currently a partner at partner at FLG Partners, LLC.  He holds a BS in business administration (accounting) from San Francisco State University.

LONI DA SILVA

Vice President of Regulatory Affairs

Loni has over 30 years of leadership experience in global regulatory affairs and strategic drug development, with more than 20 years in the ophthalmic space. She began her career at Hoffman La-Roche, and most recently served as SVP, Global Regulatory Affairs for Ophthotech, where she worked on wet and dry AMD. Loni has led global regulatory affairs for 3 start-ups and IPOs including Eyetech, Pharmasset, and Ophthotech. In addition to ophthalmics, her experience also includes oncology, antivirals, anti-infectives, hematology, pain management, and cardiology. Loni received her B.S. in microbiology from Penn State University and a M.S. in regulatory affairs from Long Island University.

DAWN PRUITT KOFFLER

Vice President of Marketing

Dawn has over 15 years of experience in sales and marketing for pharmaceutical products and medical devices. Prior to joining Oyster Point, she spent 12 years at Allergan where she served as Executive Director for consumer eye care, which included the TrueTear® device and REFRESH® brands. Before that, Dawn was Executive Director of Strategic Marketing, responsible for leading the commercial strategy for the eye care pipeline, and led consumer marketing for RESTASIS®, which earned her recognition as a Top 25 DTC marketer. She was also a member of the Global Eye Care R&D Governance Board and was the commercial lead for the integration of Oculeve and ForSight VISION5. Dawn holds a B.S. in physical therapy from California State University, Long Beach and an M.B.A. from the University of Notre Dame.

Board of Directors

MICHAEL ACKERMANN, PhD

Founder and Chairman of the Board

Michael is the founder of Oyster Point Pharma and currently serves as the Chairman of the Board. Michael is also developing two additional early-stage healthcare ventures. He was mostly recently Vice President, Neurostimulation for Allergan, plc after serving as CEO of Oculeve, Inc., which was acquired by Allergan in August 2015. He has experience in medical device and pharmaceutical development in both academic and industrial settings. He received a B.E. degree, magna cum laude, in biomedical engineering from Vanderbilt University; M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University; is a graduate of the Stanford University Biodesign Fellowship; and Vision Research Fellowship at Stanford. He has numerous patents and peer-reviewed publications.

JEFFREY NAU, PhD, MMS

President and Chief Executive Officer

Jeff has built his career on developing novel, innovative therapies for diseases of the eye, with over 15 years of experience working with biotechnology, pharmaceutical, and medical device companies. Most recently, he was VP, Clinical and Medical Affairs, at Ophthotech. Prior to that, Jeff was a Medical Science Director at Genentech working on the development of Lucentis®, a transformative drug for retinal diseases. Jeff has helped raise more than $150 million in equity for start-ups such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc. He has numerous patents and peer-reviewed publications. Jeff holds a Master’s in Medical Science and a PhD in Public Health and Epidemiology.

Ali Behbahani, MD

Director

Ali joined NEA in 2007 and is a Partner on the healthcare team. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services sectors. Prior to joining NEA, Ali worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. Ali concurrently earned his MD degree from The University of Pennsylvania School of Medicine and his MBA degree from The University of Pennsylvania Wharton School, where he graduated with Honors and was a Palmer Scholar. He graduated summa cum laude and received his bachelor’s degrees with distinction in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University. Ali serves on the boards of directors of the following companies: Adaptimmune, Arcellx, Cardionomic, CRISPR Therapeutics, CVRx, Genocea, Ivantis, Minerva Surgical, Nevro, Nkarta, Oyster Point Pharma and Solace Therapeutics.

WILLIAM J. LINK, PhD

Director

Bill specializes early-stage investing in medical devices. He is a founder and Principal of Flying L Partners and he is a founder and Managing Director of Versant Ventures.  Prior to co-founding Versant Ventures, Bill was a general partner at Brentwood Venture Capital, and has over two decades of operations experience in the healthcare industry. Bill was previously founder, chairman, and CEO of Chiron Vision, which was sold to Bausch and Lomb in 1997. Prior to Chiron Vision, Bill founded and served as President of American Medical Optics (AMO), a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the Board of AMO’s successor company, Advanced Medical Optics (AMO) which was acquired by Abbott in 2009.  AMO was acquired by Johnson and Johnson in 2016.  Before entering the healthcare industry, he was an Assistant Professor in the Department of Surgery at the Indiana University School of Medicine. Bill currently serves on the board of several private companies and three public companies, Edwards Lifesciences, Glaukos, and Second Sight Medical Products. He received his B.S., M.S., and Ph.D. from Purdue University.

Mark Murray

Director

Mark has been a CFO in the life science sector for over 30 years, working with senior executives and their boards. His eye care experience includes the successful exits of OptiMedica and Oculeve. Mark spent over 20 years with Guidant Corporation, where he was part of the senior management team and in its $1 billion IPO thru its exit in 2006 for $27 billion (by Boston Scientific and Abbott Labs). He has helped raise over $1.6 billion in equity and over $500 million in debt for public and private companies. Mark is currently a partner at partner at FLG Partners, LLC.  He holds a BS in business administration (accounting) from San Francisco State University.

CLARE OZAWA, PHD

Director

Clare is a managing director at Versant Ventures with a focus on investments in San Diego and the Bay Area. Previously, Clare was COO of Inception Sciences, where she was responsible for strategic business development, operations and finance for the Inception Sciences research sites in San Diego, Vancouver and Montreal. During her tenure at Inception, she assumed leadership roles in the creation and management of six new companies launched in partnership with academic researchers and major biopharmaceutical companies.

Before joining Inception, she was an investment professional at Versant, where she was involved in several successful investments including Flexion (NASDAQ:FLXN), Biotie (purchased by Acorda), and Quanticel (purchased by Celgene). She joined Versant from Novartis Pharma, where she worked in the Office of the CEO leading strategic initiatives for the Novartis Pharma Executive Committee.

Previously, Clare was at McKinsey & Company where she advised clients across the biopharmaceutical sector. Clare earned a Bachelor of Science degree in biological sciences with honors and distinction from Stanford University, and a Ph.D. in neurosciences from Stanford University Medical School.

1Market Scope 2016 Dry Eye Products Report: A Global Market Analysis for 2015 to 2021

2Paulsen AJ, Cruickshanks KJ, Fischer ME, Huang GH, Klein BE, Klein R, Dalton DS. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. American Journal of Ophthalmology. 2014 Apr;157(4):799-806.

3 Jennifer P. Craig, MCOptom, PhD, Kelly K. Nichols, OD, PhD,  Esen K. Akpek, MD, Barbara Caffery, OD, PhD, Harminder S. Dua, MD, PhD, Choun-Ki Joo, MD, PhD, Zuguo Liu, MD, PhD, J. Daniel Nelson, MD, Jason J. Nichols, OD, PhD, Kazuo Tsubota, MD, PhD, Fiona Stapleton, MCOptom, PhD. TFOS DEWS II Definition and Classification Report; / The Ocular Surface 15 (2017) 276-283